On October 21, AKESO recorded an Intraday Rise of 3.88% in Regular Trading, trading at HK$96.0, with turnover of HK$136 million.
The most direct catalyst was the market digesting the completion of the company’s share placement, which helped ease near-term uncertainty around funding after the financing was formally settled.
AKESO previously completed the placement of 20 million new shares at HK$97.76 per share, raising net proceeds of about HK$1.941 billion. The placed shares accounted for about 2.13% of the enlarged share capital and were allocated to no fewer than six investors. Earlier market pressure had centered on the discount placement and dilution impact; after completion, that uncertainty appears to have moderated.
Background financials also help frame the move. The company reported first-half revenue of RMB1.806 billion and a net loss of RMB447 million, while maintaining high R&D spending. The new capital is earmarked mainly for R&D, clinical trials and related infrastructure, with smaller portions for commercialization and general corporate purposes, supporting key pipeline advancement.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments